miR-638: A Promising Cancer Biomarker with Therapeutic Potential

Elham      Hasheminasabgorji; Mohammad   Amir   Mishan; Mohammad Amin   Khazeei   Tabari; Abouzar      Bagheri
doi:10.2174/1566524022666220405125900
Abstract

Background: There is an unmet need to improve the diagnosis of cancer with precise treatment strategies. Therefore, more powerful diagnostic, prognostic, and therapeutic biomarkers are needed to overcome tumor cells. microRNAs (miRNAs, miRs), as a class of small non-coding RNAs, play essential roles in cancer through the tumor-suppressive or oncogenic effects by post-transcriptional regulation of their targets. Many studies have provided shreds of evidence on aberrantly expressed miRNAs in numerous cancers and have shown that miRNAs could play potential roles as diagnostic, prognostic, and even therapeutic biomarkers in patients with cancers. Findings have revealed that miR-638 over or underexpression might play a critical role in cancer initiation, development, and progression. However, the mechanistic effects of miR-638 on cancer cells are still controversial.
Conclusion: In the present review, we have focused on the diagnostic, prognostic, and therapeutic potentials of miR-638 and discussed its mechanistic roles in various types of cancers.
Keywords: Cancer, prognosis, miR-638, diagnosis, gene regulation, biomarker.
[1]
Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage. Clin Epigenetics  2018; 10(1): 59.
 [http://dx.doi.org/10.1186/s13148-018-0492-1] [PMID:  29713393]

[2]
Karley D, Gupta D, Tiwari A. Biomarker for cancer: A great promise for future. World J Oncol  2011; 2(4): 151-7.
 [PMID:  29147241]

[3]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer  2015; 136(5): E359-86.
 [http://dx.doi.org/10.1002/ijc.29210] [PMID:  25220842]

[4]
Mishan MA, Khazeei Tabari MA, Zargari M, Bagheri A. MicroRNAs in the anticancer effects of celecoxib: A systematic review. Eur J Pharmacol  2020; 882: 173325.
 [http://dx.doi.org/10.1016/j.ejphar.2020.173325] [PMID:  32615181]

[5]
Hosseini SM, Soltani BM, Tavallaei M, et al. Clinically significant dysregulation of hsa-miR-30d-5p and hsa-let-7b expression in patients with surgically resected non-small cell lung cancer. Avicenna J Med Biotechnol  2018; 10(2): 98-104.
 [PMID:  29849986]

[6]
Ghalehnoei H, Bagheri A, Fakhar M, Mishan MA. Circulatory microRNAs: Promising non-invasive prognostic and diagnostic biomarkers for parasitic infections. Eur J Clin Microbiol Infect Dis  2020; 39(3): 395-402.
 [http://dx.doi.org/10.1007/s10096-019-03715-8] [PMID:  31617024]

[7]
Mahrooz A, Mackness M, Bagheri A, Ghaffari-Cherati M, Masoumi P. The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: The missing link between environmental and genetic regulation. Clin Biochem  2019; 73: 1-10.
 [http://dx.doi.org/10.1016/j.clinbiochem.2019.07.010] [PMID:  31351988]

[8]
Akbari Kordkheyli V, Khonakdar Tarsi A, Mishan MA, et al. Effects of quercetin on microRNAs: A mechanistic review. J Cell Biochem  2019; 120(8): 12141-55.
 [http://dx.doi.org/10.1002/jcb.28663] [PMID:  30957271]

[9]
Mishan MA, Tabari MAK, Parnian J, Fallahi J, Mahrooz A, Bagheri A. Functional mechanisms of miR-192 family in cancer. Genes Chromosomes Cancer  2020; 59(12): 722-35.
 [http://dx.doi.org/10.1002/gcc.22889] [PMID:  32706406]

[10]
Wang F, Lou JF, Cao Y, et al. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. Exp Mol Med  2015; 47(5): e162.
 [http://dx.doi.org/10.1038/emm.2015.17] [PMID:  25952770]

[11]
Tan X, Peng J, Fu Y, et al. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res  2014; 16(5): 435.
 [http://dx.doi.org/10.1186/s13058-014-0435-5] [PMID:  25228385]

[12]
Xu B, Teng LH, Silva SD, et al. The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. Cancer Med  2014; 3(1): 14-24.
 [http://dx.doi.org/10.1002/cam4.168] [PMID:  24402972]

[13]
Jaiswal R, Luk F, Gong J, Mathys J-M, Grau GER, Bebawy M. Microparticle conferred microRNA profiles--implications in the transfer and dominance of cancer traits. Mol Cancer  2012; 11(1): 37.
 [http://dx.doi.org/10.1186/1476-4598-11-37] [PMID:  22682234]

[14]
Tay Y, Tan SM, Karreth FA, Lieberman J, Pandolfi PP. Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus. Cell Rep  2014; 8(3): 714-22.
 [http://dx.doi.org/10.1016/j.celrep.2014.06.064] [PMID:  25088422]

[15]
Feng H, Liu KW, Guo P, et al. Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion. Oncogene  2012; 31(21): 2691-702.
 [http://dx.doi.org/10.1038/onc.2011.436] [PMID:  21996738]

[16]
Eppinga RD, Krueger EW, Weller SG, Zhang L, Cao H, McNiven MA. Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. Oncogene  2012; 31(10): 1228-41.
 [http://dx.doi.org/10.1038/onc.2011.329] [PMID:  21841817]

[17]
Shi M, Jiang Y, Yang L, Yan S, Wang YG, Lu XJ. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. J Cell Biochem  2018; 119(6): 4711-6.
 [http://dx.doi.org/10.1002/jcb.26650] [PMID:  29278659]

[18]
Cheng J, Chen Y, Zhao P, et al. Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance. Oncol Lett  2017; 13(5): 3859-65.
 [http://dx.doi.org/10.3892/ol.2017.5882] [PMID:  28529597]

[19]
Shigoka M, Tsuchida A, Matsudo T, et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int  2010; 60(5): 351-7.
 [http://dx.doi.org/10.1111/j.1440-1827.2010.02526.x] [PMID:  20518884]

[20]
Zhang Y, Zhang D, Jiang J, Dong L. Loss of miR-638 promotes invasion and epithelial-mesenchymal transition by targeting SOX2 in hepatocellular carcinoma. Oncol Rep  2017; 37(1): 323-32.
 [http://dx.doi.org/10.3892/or.2016.5273] [PMID:  27878280]

[21]
Ye W, Li J, Fang G, et al. Expression of microRNA 638 and sex-determining region Y-box 2 in hepatocellular carcinoma: Association between clinicopathological features and prognosis. Oncol Lett  2018; 15(5): 7255-64.
 [http://dx.doi.org/10.3892/ol.2018.8208] [PMID:  29731884]

[22]
Liu X, Wang T, Wakita T, Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology  2010; 398(1): 57-67.
 [http://dx.doi.org/10.1016/j.virol.2009.11.036] [PMID:  20006370]

[23]
Tamori A, Murakami Y, Kubo S, et al. MicroRNA expression in hepatocellular carcinoma after the eradication of chronic hepatitis virus C infection using interferon therapy. Hepatol Res  2016; 46(3): E26-35.
 [http://dx.doi.org/10.1111/hepr.12518] [PMID:  25788219]

[24]
Wan Y, Cui R, Gu J, et al. Identification of four oxidative stress-responsive microRNAs miR-34a-5p miR-1915-3p miR-638 and miR-150-3p in hepatocellular carcinoma. Oxid Med Cell Longev  2017; 2017: 5189138.
 [http://dx.doi.org/10.1155/2017/5189138] [PMID:  28811864]

[25]
Cheng J, Chen Y, Zhao P, et al. Downregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF. Oncotarget  2016; 7(21): 30702-11.
 [http://dx.doi.org/10.18632/oncotarget.8930] [PMID:  27120793]

[26]
Sun-Wada G-H, Wada Y. Vacuolar-type proton pump ATPases: Acidification and pathological relationships. Histol Histopathol  2013; 28(7): 805-15.
 [PMID:  23460142]

[27]
Morimura T, Fujita K, Akita M, Nagashima M, Satomi A. The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma. Pediatr Surg Int  2008; 24(10): 1087-94.
 [http://dx.doi.org/10.1007/s00383-008-2229-2] [PMID:  18712525]

[28]
Lu X, Chen L, Chen Y, Shao Q, Qin W. Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med  2015; 10(5): 1829-34.
 [http://dx.doi.org/10.3892/etm.2015.2758] [PMID:  26640557]

[29]
Lu Y, Zhang R, Liu S, Zhao Y, Gao J, Zhu L. ZT-25, a new vacuolar H(+)-ATPase inhibitor, induces apoptosis and protective autophagy through ROS generation in HepG2 cells. Eur J Pharmacol  2016; 771: 130-8.
 [http://dx.doi.org/10.1016/j.ejphar.2015.12.026] [PMID:  26689625]

[30]
Li J, Wang Y, Wang L, et al. Identification of rifampin-regulated functional modules and related microRNAs in human hepatocytes based on the protein interaction network. BMC Genomics  2016; 17(7) (Suppl. 7): 517.
 [http://dx.doi.org/10.1186/s12864-016-2909-6] [PMID:  27557147]

[31]
Kubota S, Chiba M, Watanabe M, Sakamoto M, Watanabe N. Secretion of small/microRNAs including miR-638 into extracellular spaces by sphingomyelin phosphodiesterase 3. Oncol Rep  2015; 33(1): 67-73.
 [http://dx.doi.org/10.3892/or.2014.3605] [PMID:  25394686]

[32]
Liu X-N, Wang S, Yang Q, Wang Y-J, Chen D-X, Zhu X-X. ESC reverses epithelial mesenchymal transition induced by transforming growth factor-β via inhibition of Smad signal pathway in HepG2 liver cancer cells. Cancer Cell Int  2015; 15(1): 114.
 [http://dx.doi.org/10.1186/s12935-015-0265-2] [PMID:  26692820]

[33]
Liu X, Yang Q, Zhang G, et al. Anti-tumor pharmacological evaluation of extracts from stellera chamaejasme L based on hollow fiber assay. BMC Complement Altern Med  2014; 14(1): 116.
 [http://dx.doi.org/10.1186/1472-6882-14-116] [PMID:  24684953]

[34]
Zhao P, Zhang BL, Liu K, Qin B, Li ZH. Overexpression of miR-638 attenuated the effects of hypoxia/reoxygenation treatment on cell viability, cell apoptosis and autophagy by targeting ATG5 in the human cardiomyocytes. Eur Rev Med Pharmacol Sci  2018; 22(23): 8462-71.
 [PMID:  30556888]

[35]
Morii A, Ogawa R, Watanabe A, et al. Utilization of microRNAs with decreased expression levels in response to X-ray irradiation for fine-tuning radiation-controlled gene regulation. Int J Mol Med  2013; 32(1): 9-16.
 [http://dx.doi.org/10.3892/ijmm.2013.1360] [PMID:  23612713]

[36]
Xu Q, Zhang Q, Dong M, Yu Y. MicroRNA-638 inhibits the progression of breast cancer through targeting HOXA9 and suppressing Wnt/β-cadherin pathway. World J Surg Oncol  2021; 19(1): 247.
 [http://dx.doi.org/10.1186/s12957-021-02363-7] [PMID:  34416888]

[37]
Li M, Wang J, Liu H. Downregulation of miR-638 promotes progression of breast cancer and is associated with prognosis of breast cancer patients. OncoTargets Ther  2018; 11: 6871-7.
 [http://dx.doi.org/10.2147/OTT.S182034] [PMID:  30349320]

[38]
Nicoloso MS, Sun H, Spizzo R, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res  2010; 70(7): 2789-98.
 [http://dx.doi.org/10.1158/0008-5472.CAN-09-3541] [PMID:  20332227]

[39]
Zavala V, Pérez-Moreno E, Tapia T, Camus M, Carvallo P. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival. Cancer Biomark  2016; 16(1): 99-107.
 [http://dx.doi.org/10.3233/CBM-150545] [PMID:  26835710]

[40]
Shi M, Ma F, Liu J, et al. A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy. Breast Cancer Res Treat  2017; 166(1): 109-16.
 [http://dx.doi.org/10.1007/s10549-017-4395-1] [PMID:  28744749]

[41]
Zhang Y, Han G, Fan B, et al. Green tea (-)-epigallocatechin-3-gallate down-regulates VASP expression and inhibits breast cancer cell migration and invasion by attenuating Rac1 activity. Eur J Pharmacol  2009; 606(1-3): 172-9.
 [http://dx.doi.org/10.1016/j.ejphar.2008.12.033] [PMID:  19171136]

[42]
Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta  2012; 413(13-14): 1058-65.
 [http://dx.doi.org/10.1016/j.cca.2012.02.016] [PMID:  22387599]

[43]
Tang M, Tian Y, Li D, et al. TNF-α mediated increase of HIF-1α inhibits VASP expression, which reduces alveolar-capillary barrier function during acute lung injury (ALI). PLoS One  2014; 9(7): e102967.
 [http://dx.doi.org/10.1371/journal.pone.0102967] [PMID:  25051011]

[44]
Su K, Tian Y, Wang J, et al. HIF-1α acts downstream of TNF-α to inhibit vasodilator-stimulated phosphoprotein expression and modulates the adhesion and proliferation of breast cancer cells. DNA Cell Biol  2012; 31(6): 1078-87.
 [http://dx.doi.org/10.1089/dna.2011.1563] [PMID:  22320863]

[45]
Han G, Fan B, Zhang Y, et al. Positive regulation of migration and invasion by vasodilator-stimulated phosphoprotein via Rac1 pathway in human breast cancer cells. Oncol Rep  2008; 20(4): 929-39.
 [PMID:  18813837]

[46]
Hu P-C, Li K, Tian Y-H, et al. CREB1/Lin28/miR-638/VASP Interactive Network Drives the Development of Breast Cancer. Int J Biol Sci  2019; 15(12): 2733-49.
 [http://dx.doi.org/10.7150/ijbs.36854] [PMID:  31754343]

[47]
Lin Q-Y, Wang J-Q, Wu L-L, Zheng W-E, Chen P-R. miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2. Breast Cancer  2019; 1-12.
 [PMID:  31410735]

[48]
Ko CCH, Chia WK, Selvarajah GT, Cheah YK, Wong YP, Tan GC. The role of breast cancer stem cell-related biomarkers as prognostic factors. Diagnostics (Basel)  2020; 10(9): 721.
 [http://dx.doi.org/10.3390/diagnostics10090721] [PMID:  32961774]

[49]
Ghafouri-Fard S, Hajiesmaeili M, Shoorei H, Bahroudi Z, Taheri M, Sharifi G. The impact of lncRNAs and miRNAs in regulation of function of cancer stem cells and progression of cancer. Front Cell Dev Biol  2021; 9: 696820.
 [http://dx.doi.org/10.3389/fcell.2021.696820] [PMID:  34368145]

[50]
Ren Y, Chen Y, Liang X, Lu Y, Pan W, Yang M. MiRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3. Cancer Lett  2017; 390: 126-36.
 [http://dx.doi.org/10.1016/j.canlet.2017.01.009] [PMID:  28108314]

[51]
Zhao G, Li Y, Wang T. Potentiation of docetaxel sensitivity by miR-638 via regulation of STARD10 pathway in human breast cancer cells. Biochem Biophys Res Commun  2017; 487(2): 255-61.
 [http://dx.doi.org/10.1016/j.bbrc.2017.04.045] [PMID:  28412359]

[52]
Ma K, Pan X, Fan P, et al. Loss of miR-638 in vitro promotes cell invasion and a mesenchymal-like transition by influencing SOX2 expression in colorectal carcinoma cells. Mol Cancer  2014; 13(1): 118.
 [http://dx.doi.org/10.1186/1476-4598-13-118] [PMID:  24885288]

[53]
Zhang J, Fei B, Wang Q, et al. MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma. Oncotarget  2014; 5(23): 12083-96.
 [http://dx.doi.org/10.18632/oncotarget.2499] [PMID:  25301729]

[54]
Kahlert C, Klupp F, Brand K, et al. Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci  2011; 102(10): 1799-807.
 [http://dx.doi.org/10.1111/j.1349-7006.2011.02023.x] [PMID:  21722265]

[55]
Gattolliat C-H, Uguen A, Pesson M, et al. MicroRNA and targeted mRNA expression profiling analysis in human colorectal adenomas and adenocarcinomas. Eur J Cancer  2015; 51(3): 409-20.
 [http://dx.doi.org/10.1016/j.ejca.2014.12.007] [PMID:  25586944]

[56]
Yin Y, Song M, Gu B, et al. Systematic analysis of key miRNAs and related signaling pathways in colorectal tumorigenesis. Gene  2016; 578(2): 177-84.
 [http://dx.doi.org/10.1016/j.gene.2015.12.015] [PMID:  26692142]

[57]
Lu M, Zhou X, Zheng C-G, Liu F-J. Expression profiling of miR-96 miR-584 and miR-422a in colon cancer and their potential involvement in colon cancer pathogenesis. Trop J Pharm Res  2016; 15(12): 2535-42.
 [http://dx.doi.org/10.4314/tjpr.v15i12.1]

[58]
Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One  2014; 9(4): e92921.
 [http://dx.doi.org/10.1371/journal.pone.0092921] [PMID:  24705249]

[59]
Hosseini M, Khatamianfar S, Hassanian SM, et al. Exosome-encapsulated microRNAs as potential circulating biomarkers in colon cancer. Curr Pharm Des  2017; 23(11): 1705-9.
 [http://dx.doi.org/10.2174/1381612822666161201144634] [PMID:  27908272]

[60]
Yan S, Han B, Gao S, et al. Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget  2017; 8(36): 60149-58.
 [http://dx.doi.org/10.18632/oncotarget.18557] [PMID:  28947960]

[61]
Yan S, Dang G, Zhang X, et al. Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients. Oncotarget  2017; 8(42): 72220-6.
 [http://dx.doi.org/10.18632/oncotarget.19689] [PMID:  29069781]

[62]
Chiba M, Kawamura C, Kubota S, Sato K, Sakai A. Exosomes released from pancreatic cancer cells are heterogeneous particle populations. Biomed Res (Aligarh)  2018; 29(14): 2988-91.

[63]
Zhang W, Huang Z, Huang M, Zeng J. Predicting severe enterovirus 71-infected hand foot and mouth disease: Cytokines and chemokines. Mediators Inflamm 2020.

[64]
Nie Z, Cao F, Li B, Yuan L. EV71 infection causes differential expression of microRNAs in colon carcinoma cells. Int J Clin Exp Pathol  2016; 9(10): 10363-72.

[65]
Shen Y, Ding Y, Ma Q, et al. Identification of novel circulating miRNA biomarkers for the diagnosis of esophageal squamous cell carcinoma and squamous dysplasia. Epidemiol Prev Biomarkers 2019.
 [http://dx.doi.org/10.1158/1055-9965.EPI-18-1199]

[66]
Liu N, Cui RX, Sun Y, et al. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer  2014; 134(6): 1359-68.
 [http://dx.doi.org/10.1002/ijc.28468] [PMID:  23999999]

[67]
Tang K-L, Tang H-Y, Du Y, Tian T, Xiong SJ. MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/β-catenin pathway by targeting phospholipase D1. Artif Cells Nanomed Biotechnol  2019; 47(1): 3278-85.
 [http://dx.doi.org/10.1080/21691401.2019.1647222] [PMID:  31379206]

[68]
Zhang X, Wei J, Zhou L, et al. A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma. Carcinogenesis  2013; 34(10): 2309-13.
 [http://dx.doi.org/10.1093/carcin/bgt213] [PMID:  23749772]

[69]
Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One  2009; 4(5): e5532.
 [http://dx.doi.org/10.1371/journal.pone.0005532] [PMID:  19440243]

[70]
Liu X, Li P, Yun Y, et al. Prognostic value of plasma miR-638 in patients with acute myeloid leukemia. Int J Clin Exp Pathol  2017; 10(1): 550-5.

[71]
Eyholzer M, Schmid S, Wilkens L, Mueller BU, Pabst T. The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer  2010; 103(2): 275-84.
 [http://dx.doi.org/10.1038/sj.bjc.6605751] [PMID:  20628397]

[72]
Lin Y, Li D, Liang Q, et al. miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2. J Biol Chem  2015; 290(3): 1818-28.
 [http://dx.doi.org/10.1074/jbc.M114.599191] [PMID:  25451924]

[73]
He M, Lin Y, Tang Y, et al. miR-638 suppresses DNA damage repair by targeting SMC1A expression in terminally differentiated cells. Aging (Albany NY)  2016; 8(7): 1442-56.
 [http://dx.doi.org/10.18632/aging.100998] [PMID:  27405111]

[74]
Zhu D-X, Zhu W, Fang C, et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis  2012; 33(7): 1294-301.
 [http://dx.doi.org/10.1093/carcin/bgs179] [PMID:  22610076]

[75]
Zhang J, Zhao A, Sun L, et al. Selective surface marker and miRNA profiles of CD34+ blast-derived microvesicles in chronic myelogenous leukemia. Oncol Lett  2017; 14(2): 1866-74.
 [http://dx.doi.org/10.3892/ol.2017.6336] [PMID:  28789422]

[76]
Shi Y, Liu T-Y, Song M-Y, Chen L, Liu J, Gao S. Reproducibility of quantitative real-time PCR analysis in microRNA expression profiling and comparisons with microarray assays in diffuse large B-cell lymphoma patients. Int J Clin Exp Med  2019; 12(5): 5776-84.

[77]
Wilting SM, Verlaat W, Jaspers A, et al. Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics  2013; 8(2): 220-8.
 [http://dx.doi.org/10.4161/epi.23605] [PMID:  23324622]

[78]
Wei H, Zhang JJ, Tang QL. MiR-638 inhibits cervical cancer metastasis through Wnt/β-catenin signaling pathway and correlates with prognosis of cervical cancer patients. Eur Rev Med Pharmacol Sci  2017; 21(24): 5587-93.
 [PMID:  29271990]

[79]
Kan CW, Hahn MA, Gard GB, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer  2012; 12(1): 627.
 [http://dx.doi.org/10.1186/1471-2407-12-627] [PMID:  23272653]

[80]
Saral MA, Tuncer SB, Odemis DA, et al. New biomarkers in peripheral blood of patients with ovarian cancer: High expression levels of miR-16-5p miR-17-5p and miR-638. Arch Gynecol Obstet  2022; 305(1): 193-201.
 [http://dx.doi.org/10.1007/s00404-021-06138-z] [PMID:  34370073]

[81]
Abdollahi A, Rahmati S, Ghaderi B, et al. A combined panel of circulating microRNA as a diagnostic tool for detection of the non-small cell lung cancer. QJM  2019; 112(10): 779-85.
 [http://dx.doi.org/10.1093/qjmed/hcz158] [PMID:  31236600]

[82]
Xu P, Wang L, Xie X, et al. Hsa_circ_0001869 promotes NSCLC progression via sponging miR-638 and enhancing FOSL2 expression. Aging (Albany NY)  2020; 12(23): 23836-48.
 [http://dx.doi.org/10.18632/aging.104037] [PMID:  33221767]

[83]
Fang K, Chen X, Qiu F, Xu J, Xiong H, Zhang Z. Serumderived
exosomes-mediated circular RNA ARHGAP10
modulates the progression of non-small-cell lung cancer
through the miR-638/FAM83F axis. Cancer Biother
Radiopharm  2020; cbr.2019.3534.
 [http://dx.doi.org/10.1089/cbr.2019.3534] [PMID:  32783691]

[84]
Zhang Y, Yao H, Li Y, et al. Circular RNA TADA2A promotes proliferation and migration via modulating of miR-638/KIAA0101 signal in non-small cell lung cancer. Oncol Rep  2021; 46(3): 1-12.
 [http://dx.doi.org/10.3892/or.2021.8152]

[85]
Chen W-S, Hou J-N, Guo Y-B, et al. Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway. J Exp Clin Cancer Res  2011; 30(1): 17.
 [http://dx.doi.org/10.1186/1756-9966-30-17] [PMID:  21303527]

[86]
Zhang Y, Zhang G-B, Xu X-M, et al. Suppression of growth of A549 lung cancer cells by waltonitone and its mechanisms of action. Oncol Rep  2012; 28(3): 1029-35.
 [http://dx.doi.org/10.3892/or.2012.1869] [PMID:  22710478]

[87]
Kim KB, Kim K, Bae S, et al. MicroRNA-1290 promotes asiatic acid induced apoptosis by decreasing BCL2 protein level in A549 non small cell lung carcinoma cells. Oncol Rep  2014; 32(3): 1029-36.
 [http://dx.doi.org/10.3892/or.2014.3319] [PMID:  25016979]

[88]
Xia Y, Wu Y, Liu B, Wang P, Chen Y. Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC. FEBS Lett  2014; 588(14): 2238-45.
 [http://dx.doi.org/10.1016/j.febslet.2014.05.002] [PMID:  24842609]

[89]
Li D, Wang Q, Liu C, et al. Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. Toxicol Sci  2012; 125(2): 382-91.
 [http://dx.doi.org/10.1093/toxsci/kfr299] [PMID:  22048643]

[90]
Chang H, Kim N, Park JH, et al. Different microRNA expression levels in gastric cancer depending on Helicobacter pylori infection. Gut Liver  2015; 9(2): 188-96.
 [http://dx.doi.org/10.5009/gnl13371] [PMID:  25167801]

[91]
Yoon SO, Kim EK, Lee M, et al. NOVA1 inhibition by miR-146b-5p in the remnant tissue microenvironment defines occult residual disease after gastric cancer removal. Oncotarget  2016; 7(3): 2475-95.
 [http://dx.doi.org/10.18632/oncotarget.6542] [PMID:  26673617]

[92]
Shen Y, Chen H, Gao L, et al. MiR-638 acts as a tumor suppressor gene in gastric cancer. Oncotarget  2017; 8(64): 108170-80.
 [http://dx.doi.org/10.18632/oncotarget.22567] [PMID:  29296232]

[93]
Zhang J, Bian Z, Zhou J, et al. MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma. Protein Cell  2015; 6(9): 680-8.
 [http://dx.doi.org/10.1007/s13238-015-0187-8] [PMID:  26250158]

[94]
Zhao LY, Tong DD, Xue M, et al. MeCP2, a target of miR-638, facilitates gastric cancer cell proliferation through activation of the MEK1/2-ERK1/2 signaling pathway by upregulating GIT1. Oncogenesis  2017; 6(7): e368.
 [http://dx.doi.org/10.1038/oncsis.2017.60] [PMID:  28759023]

[95]
Zhao LY, Yao Y, Han J, et al. miR-638 suppresses cell proliferation in gastric cancer by targeting Sp2. Dig Dis Sci  2014; 59(8): 1743-53.
 [http://dx.doi.org/10.1007/s10620-014-3087-5] [PMID:  24623314]

[96]
Wang K, Xu L, Pan L, Xu K, Li G. The functional BRCA1 rs799917 genetic polymorphism is associated with gastric cancer risk in a Chinese Han population. Tumour Biol  2015; 36(1): 393-7.
 [http://dx.doi.org/10.1007/s13277-014-2655-9] [PMID:  25266802]

[97]
Sand M, Skrygan M, Sand D, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol  2012; 167(4): 847-55.
 [http://dx.doi.org/10.1111/j.1365-2133.2012.11022.x] [PMID:  22540308]

[98]
Bhattacharya A, Schmitz U, Raatz Y, et al. miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy. Oncotarget  2015; 6(5): 2966-80.
 [http://dx.doi.org/10.18632/oncotarget.3070] [PMID:  25650662]

[99]
Ludwig N, Nourkami-Tutdibi N, Backes C, et al. Circulating serum miRNAs as potential biomarkers for nephroblastoma. Pediatr Blood Cancer  2015; 62(8): 1360-7.
 [http://dx.doi.org/10.1002/pbc.25481] [PMID:  25787821]

[100]
Zuntini M, Salvatore M, Pedrini E, et al. MicroRNA profiling of multiple osteochondromas: Identification of disease-specific and normal cartilage signatures. Clin Genet  2010; 78(6): 507-16.
 [http://dx.doi.org/10.1111/j.1399-0004.2010.01490.x] [PMID:  20662852]

[101]
Wang XX, Liu J, Tang YM, Hong L, Zeng Z, Tan GH. MicroRNA-638 inhibits cell proliferation by targeting suppress PIM1 expression in human osteosarcoma. Tumour Biol  2017; 37(12): 16367-75.
 [http://dx.doi.org/10.1007/s13277-016-5379-1] [PMID:  28050866]

[102]
Zhou X, Chen J, Xiao Q, et al. MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells. Biosci Rep  2018; 38(1): BSR20171017.
 [http://dx.doi.org/10.1042/BSR20171017] [PMID:  29263143]

[103]
Parasramka MA, Ali S, Banerjee S, Deryavoush T, Sarkar FH, Gupta S. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. Mol Nutr Food Res  2013; 57(2): 235-48.
 [http://dx.doi.org/10.1002/mnfr.201200297] [PMID:  23293055]

[104]
Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science  2008; 319(5867): 1244-7.
 [http://dx.doi.org/10.1126/science.1153124] [PMID:  18309083]

[105]
Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem  2010; 285(23): 17442-52.
 [http://dx.doi.org/10.1074/jbc.M110.107821] [PMID:  20353945]

[106]
Castro-Magdonel BE, Orjuela M, Camacho J, et al. miRNome landscape analysis reveals a 30 miRNA core in retinoblastoma. BMC Cancer  2017; 17(1): 458.
 [http://dx.doi.org/10.1186/s12885-017-3421-3] [PMID:  28668075]

[107]
Song B-K, Kim KM, Choi K-D, Im WT. Production of the rare ginsenoside Rh2-MIX (20(S)-Rh2, 20(R)-Rh2, Rk2, and Rh3) by enzymatic conversion combined with acid treatment and evaluation of its anti-cancer activity. J Microbiol Biotechnol  2017; 27(7): 1233-41.
 [http://dx.doi.org/10.4014/jmb.1701.01077] [PMID:  28478658]

[108]
Li M, Zhang D, Cheng J, Liang J, Yu F. Ginsenoside Rh2 inhibits proliferation but promotes apoptosis and autophagy by down-regulating microRNA-638 in human retinoblastoma cells. Exp Mol Pathol  2019; 108: 17-23.
 [http://dx.doi.org/10.1016/j.yexmp.2019.03.004] [PMID:  30853612]

[109]
Liu W, Ma W, Yuan Y, Zhang Y, Sun S. Circular RNA hsa_circRNA_103809 promotes lung cancer progression via facilitating ZNF121-dependent MYC expression by sequestering miR-4302. Biochem Biophys Res Commun  2018; 500(4): 846-51.
 [http://dx.doi.org/10.1016/j.bbrc.2018.04.172] [PMID:  29698681]

[110]
Chen Z, Duan X. hsa_circ_0000177-miR-638-FZD7-Wnt signaling Cascade contributes to the malignant behaviors in glioma. DNA Cell Biol  2018; 37(9): 791-7.
 [http://dx.doi.org/10.1089/dna.2018.4294] [PMID:  30010402]

[111]
Zheng DH, Wang X, Lu LN, et al. MiR-638 serves as a tumor suppressor by targeting HOXA9 in glioma. Eur Rev Med Pharmacol Sci  2018; 22(22): 7798-806.
 [PMID:  30536324]

[112]
Wei Z, Zhou C, Liu M, et al. MicroRNA involvement in a metastatic non-functioning pituitary carcinoma. Pituitary  2015; 18(5): 710-21.
 [http://dx.doi.org/10.1007/s11102-015-0648-3] [PMID:  25862551]

[113]
Fabbri M. MicroRNAs and cancer: Towards a personalized medicine. Curr Mol Med  2013; 13(5): 751-6.
 [http://dx.doi.org/10.2174/1566524011313050006] [PMID:  23642056]

[114]
Hu L, Huang M, Yuan Q, Kong F. Prognostic and clinicopathological significance of miR-638 in cancer patients: A meta-analysis. Medicine (Baltimore)  2021; 100(15): e25441.
 [http://dx.doi.org/10.1097/MD.0000000000025441] [PMID:  33847647]
Rights & Permissions Print Cite
Article Metrics
38
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1566524022666220405125900	Print ISSN 1566-5240
Publisher Name Bentham Science Publisher	Online ISSN 1875-5666
Current Molecular Medicine

miR-638: A Promising Cancer Biomarker with Therapeutic Potential

Abstract

Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders

Current Molecular Medicine

miR-638: A Promising Cancer Biomarker with Therapeutic Potential

Abstract

Call for Papers in Thematic Issues

Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders

Related Journals

Related Books

Related Articles
